Novartis AG ADR (NVS)vsStevanato Group SpA (STVN)
NVS
Novartis AG ADR
$145.23
+0.01%
HEALTHCARE · Cap: $277.42B
STVN
Stevanato Group SpA
$18.28
+0.27%
HEALTHCARE · Cap: $4.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4602% more annual revenue ($56.58B vs $1.20B). NVS leads profitability with a 23.9% profit margin vs 11.7%. NVS appears more attractively valued with a PEG of 2.59. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$145.23
$35.11 premium
Margin of Safety
+81.1%
Fair Value
$82.46
Current Price
$18.28
$64.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Premium valuation, high expectations priced in
2.9% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : STVN
The strongest argument for STVN centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a declining stock while STVN is a value play — different risk/reward profiles.
STVN carries more volatility with a beta of 0.76 — expect wider price swings.
STVN is growing revenue faster at 6.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 46/100), backed by strong 23.9% margins. STVN offers better value entry with a 81.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a prominent global leader in advanced drug delivery systems, offering innovative integrated solutions specifically designed for the pharmaceutical and biotechnology industries. The company specializes in the design and production of high-quality glass and polymer packaging for injectable medications, enhancing the efficiency and reliability of drug administration. With a dedicated focus on quality, sustainability, and technological advancement, Stevanato is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector, making it an appealing investment opportunity for institutional investors seeking exposure to healthcare innovation.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?